D. Boral Capital Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 price objective on the stock.

A number of other brokerages also recently commented on IBRX. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. BTIG Research initiated coverage on ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $2.94 on Thursday. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The stock has a market cap of $2.05 billion, a PE ratio of -3.20 and a beta of 0.86. The firm has a 50-day simple moving average of $3.74 and a 200 day simple moving average of $4.25.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in IBRX. Mutual Advisors LLC bought a new position in shares of ImmunityBio during the 4th quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in ImmunityBio during the third quarter worth $51,000. Barclays PLC lifted its holdings in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after acquiring an additional 202,248 shares during the period. XTX Topco Ltd boosted its stake in shares of ImmunityBio by 309.4% in the 3rd quarter. XTX Topco Ltd now owns 92,910 shares of the company’s stock valued at $346,000 after purchasing an additional 70,215 shares in the last quarter. Finally, State Street Corp increased its position in shares of ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.